This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
Inflammatory Bowel Disease and Colorectal Cancer
by
Jacopo Fanizza
Jacopo Fanizza 1,
Sarah Bencardino
Sarah Bencardino 1
,
Mariangela Allocca
Mariangela Allocca 1,
Federica Furfaro
Federica Furfaro 1,
Alessandra Zilli
Alessandra Zilli 1,
Tommaso Lorenzo Parigi
Tommaso Lorenzo Parigi 1,
Gionata Fiorino
Gionata Fiorino 2
,
Laurent Peyrin-Biroulet
Laurent Peyrin-Biroulet 3,4,5,6,7,8,
Silvio Danese
Silvio Danese 1
and
Ferdinando D’Amico
Ferdinando D’Amico 1,*
1
Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, 20132 Milan, Italy
2
IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, 00152 Rome, Italy
3
Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France
4
INSERM, NGERE, University of Lorraine, F-54000 Nancy, France
5
INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France
6
FHU-CURE, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France
7
Groupe Hospitalier Privè Ambroise Parè—Hartmann, Paris IBD Center, 92200 Neuilly sur Seine, France
8
Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC H4A 3J1, Canada
*
Author to whom correspondence should be addressed.
Submission received: 29 July 2024
/
Revised: 21 August 2024
/
Accepted: 22 August 2024
/
Published: 23 August 2024
Simple Summary
Patients with inflammatory bowel disease (IBD) face an increased risk of colorectal cancer, necessitating a surveillance program to detect early signs of cancer. Evaluating the effectiveness and safety of IBD medications in patients with a history of previous or active cancer, as well as assessing antineoplastic drugs in those with IBD, is crucial. This review outlines known risk factors, surveillance, and appropriate management strategies for patients with IBD and concomitant history of cancer.
Abstract
Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn’s disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease in the incidence of CRC among IBD patients. Currently, the management of patients with IBD who have a history of or ongoing active malignancy is an unmet need. This involves balancing the risk of cancer recurrence/progression with the potential exacerbation of IBD if the medications are discontinued. The objective of this review is to provide an updated summary of the epidemiology, causes, risk factors, and surveillance approaches for CRC in individuals with IBD, and to offer practical guidance on managing IBD patients with history of previous or active cancer.
Share and Cite
MDPI and ACS Style
Fanizza, J.; Bencardino, S.; Allocca, M.; Furfaro, F.; Zilli, A.; Parigi, T.L.; Fiorino, G.; Peyrin-Biroulet, L.; Danese, S.; D’Amico, F.
Inflammatory Bowel Disease and Colorectal Cancer. Cancers 2024, 16, 2943.
https://doi.org/10.3390/cancers16172943
AMA Style
Fanizza J, Bencardino S, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S, D’Amico F.
Inflammatory Bowel Disease and Colorectal Cancer. Cancers. 2024; 16(17):2943.
https://doi.org/10.3390/cancers16172943
Chicago/Turabian Style
Fanizza, Jacopo, Sarah Bencardino, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese, and Ferdinando D’Amico.
2024. "Inflammatory Bowel Disease and Colorectal Cancer" Cancers 16, no. 17: 2943.
https://doi.org/10.3390/cancers16172943
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.